Summary: To clarify the optimal timing of second look operation (SLO) for advanced ovarian cancer, we retrospectively reviewed the records of 53 patients with FIGO stage 2, 3 and 4 epithelial ovarian cancer. SLOs were performed more than 12 months after primary surgery in 35 patients (late SLOs), and immediately after first-line chemotherapy in 18 patients (early SLOs). We examined data on SLO findings and patients' clinical courses. SLO findings were positive 5 (27.7%) of 18 in the early SLO group and in 11 (31.4%) of 35 in late SLO group. Positive findings were detected by washing cytology in 3 (60%) of the 5 in the early SLO group compared with 2 (18.2%) of the 11 in the late SLO group. Patients with microscopic disease had better prognosis than patients with macro lesions. False-negative SLO findings were 30.8% in the early SLO group and 12.5% in the late SLO group . All patients who recurred after negative SLOs had grade 2 and 3 tumors. The benefits of SLO were limited to accurate evaluation of first-line chemotherapy and early detection of persistent disease. In these implications, early performance of SLO is recommended.
Introduction
While the second look operation (SLO) is routinely used to assess the status of patients with epithelial ovarian cancer, recent studies have suggested that although SLO may be of diagnostic value, they do not improve the patients' survivals (Ho et al. 1987; Luesley et al. 1988; Sonnendecker, 1988; Miller et al. 1992; Potter et al. 1992) . It is generally accepted that patients with persistent disease at SLO showed poor prognosis, while patients without disease showed better prognosis but some of them experience recurrence (Copeland and Gershenson, 1986; Podratz and Cliby, 1994) . Traditionally SLOs were performed at about one year after primary surgery without any randomized trial. In recent years, this procedure tends to be performed in the earlier opportunity. In this All patients had undergone primary surgery and subsequent Cis-Platinumbased adjuvant systemic chemotherapy. They received SLO after being classified as disease-free following therapy based on non-invasive evaluations including physical examination, assays of serum tumor markers, computed tomography (CT) and ultrasonography.
SLOs were performed under the general anesthesia. A midline incision was made along the scar of the primary surgery and entire pelvic and abdominal cavities were examined, with particular attention paid to the area which had residual tumor at the time of the primary surgery. 
Results
Early SLO group included 5 SLO positives of 18 patients. Three of these five SLO positives were decided by washing cytology only (microscopic positive). Otherwise, only 2 patients of 11 were microscopic positive in late SLO group. The mortality rate of SLO positives were 60% (3/5) in early SLOs and 81.8% (9/11) in late SLOs (no statistically significant) ( Table 2 ). Survival curve of early and late SLOs were seen in Fig. 1 . There was no statistical significance between early and late SLOs in overall survival probability by generalized Wilcoxon test (P>0.05). Four patients of early SLOs died in first 24 months. Two of them who had macroscopic lesion in upper abdomen at SLO refused further treatment and died at 9 and 14 months after SLO. One patient received laparotomy at 3 months after primary surgery because of bowel obstruction. While no residual lesion was confirmed, CA125 level elevated at three months after finishing the first line therapy and finally died 9 months after primary surgery. Another patients had microscopic positive SLO and died of therapeutic toxicity of second line therapy at 8 months after SLO. The more number of SLO negatives Summary of the results of early and late SLOs. recurrence: patients who progressed disease and were detected recurrence by imaging study after SLO. microscopic SLO(P): number of patients who were decided as SLO positive by washing cytology only. mortality of SLO(P): mortality of the patients of SLO positives. recurrence after SLO(N): number of patients who showed clinical recurrence after negative SLO. mortality of SLO(N): mortality of the patients of SLO negatives. Patients received SLO within 11 months after primary surgery (early SLO: n=18). Patients received SLO more than 12 months after primary surgery (late SLO: n=35). The difference in survival was not statistically significant. (P>0.05) advances of imaging tests and tumor marker assays, 60% of patients with advanced ovarian cancer classified as complete responders are found to have occult disease at SLO (Podratzs and Cliby, 1994) . Most of SLO positives eventually died of cancer-related causes despite receiving salvage therapy. Criticisms of the use of SLO are based on the absence of prospective data documenting enhanced survival in patients who undergo this procedure (Ho et al. 1987; Luesley et al. 1988; Sonnendecker, 1988; Miller et al. 1992; Potter et al. 1992; Podratzs et al. 1994 ). In addition, 20 to 50 % of SLO-negative patients experienced recurrence (Copeland et al. 1994; Podratz and Cliby, 1994) , suggesting that although SLO has diagnostic value, it has no beneficial impact on patients' outcome.
Nevertheless, the significance of SLO should be discussed focusing on when they are to be performed. In the present study, the number of microscopic positive was higher in the early SLO group than in the late SLO group (2/5 and 2/11 respectively). Survival curve in the microscopic positives was favorable than in the macroscopic positives. Podoratz and Cliby (1994) have suggested that treatment of established microscopic disease prior to the development of clinically demonstrable disease improved survival. As a second-line therapy, intraperitoneal platinum administration was recommended for small volume residual tumor (Muggia et al. 1993; Piver et al. 1994) . Early SLO group included four patients who died in 24 months. In two of them with macroscopic positive SLO, their SLO should have been canceled, if they had received upper abdominal CT examination. One patient received too early SLO by bowel obstruction. Another patient unexpectedly died of toxicity during second-line chemotherapy. Although, there was no statistically difference in the overall survival between early and late SLO groups, because the early SLO patients have more chance to be detected their persistent disease minimally, they have more possibility to be cured excluding these four patients. In the late SLO group, 9 of 11 had macroscopic disease, indicating that late SLOs were of diagnostic value only because of its low curative rate. Van Lith et al. (1989) performed early SLO after three courses chemotherapy (six courses were scheduled as first-line therapy) to assess chemotherapeutic effect. Their trial of performing SLO before completion of first-line therapy may mislead in assessing therapeutic effect for partial responders. In the present study, early SLOB were performed within 6 weeks of completion of first-line chemotherapy except one case, providing timely evaluation of the effects of first-line therapy and facilitating an early decision about any necessary changes in therapeutic strategy.
The SLO false-negative rate was higher in the early SLO group than in the late SLO group in the present study. However, the interval from a pathological CR to appearance of clinical recurrence varied widely among patients, making it difficult to establish the optimal timing of SLO with no false negatives. Previous retrospective studies have identified high-grade tumor, the amount of tumor remaining after primary operation, and patient age as the risk factors for a recurrence after negative SLO (Rubin et al. 1991; Miller et al. 1992; Copeland et al. 1994; Podratz and Cliby, 1994) . In the present study, the disease stage and the tumor grade were risk factors for recurrence. Therefore, consolidation therapy is strongly recommended for patients with stage 3 or 4 and grade 2 or 3 tumors or clear cell carcinoma. Appropriate consolidation therapy may reduce falsenegative rate (Menczer et al. 1992; Tarraza et al. 1993 ).
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